Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Dec 20;44(1):6.
doi: 10.1007/s10875-023-01617-1.

Letermovir for CMV Prophylaxis in Very High-Risk Pediatric Hematopoietic Stem Cell Transplantation Recipients for Inborn Errors of Immunity

Thibaut César  1 , Minh P Le  2   3 , Roman Klifa  1   4 , Martin Castelle  1 , Benjamin Fournier  1   4   5 , Romain Lévy  1   4   6 , Marwa Chbihi  1   4 , Virginie Courteille  7 , Despina Moshous  1   4   7   8 , Stéphane Blanche  1   4 , Mickaël Alligon  7 , Marianne Leruez-Ville  9 , Gilles Peytavin  2   10 , Pierre Frange  9 , Bénédicte Neven  11   12   13
Affiliations

Letermovir for CMV Prophylaxis in Very High-Risk Pediatric Hematopoietic Stem Cell Transplantation Recipients for Inborn Errors of Immunity

Thibaut César et al. J Clin Immunol. .

Abstract

The burden of CMV infection and disease is important in pediatric hematopoietic stem cell transplantation (HSCT), notably in the subgroup of patients with inborn errors of immunity (IEIs). Letermovir (LMV) is now a standard of care for CMV prophylaxis in adult sero-positive (R+) recipients, but is not yet labeled for children. Published pediatric studies are still scarce. We report a monocentric real-life use of LMV in 36 HSCT pediatric recipients with IEIs considered at high-risk of CMV infection including 14 patients between 2 and 12 months of age. A homogenous dosage proportional to the body surface area was used. Pharmacokinetic (PK) was performed in 8 patients with a median of 6 years of age (range 0,6;15). The cumulative incidence of clinically significant CMV infections (CS-CMVi) and the overall survival of patients under LMV were compared to a very similar historical cohort under (val)aciclovir prophylaxis. LMV tolerance was good. As compared to the historical cohort, the incidence of CS-CMVi was significantly lower in LMV group (5 out of 36 transplants (13.9%) versus 28 of the 62 HSCT (45.2%)) (p = 0.002). Plasma LMV exposures did not significantly differ with those reported in adult patients. In this high-risk pediatric HSCT cohort transplanted for IEIs, CMV prophylaxis with LMV at a homogenous dosage was well tolerated and effective in preventing CS-CMVi compared with a historical cohort.

Keywords: CMV Prophylaxis; Hematopoietic stem cell Transplant; Inborn Errors of Immunity; Letermovir; Pediatrics; Pharmacokinetics.

PubMed Disclaimer

References

    1. Ljungman P, et al. Donor cytomegalovirus status influences the outcome of allogeneic stem cell transplant: a study by the European group for blood and marrow transplantation. Clin Infect Dis off Publ Infect Dis Soc Am. 2014;59(4):473–81. https://doi.org/10.1093/cid/ciu364 .
    1. Helou GE, Razonable RR. Letermovir for the prevention of cytomegalovirus Infection and Disease in transplant recipients: an evidence-based review. Infect Drug Resist. 2019;12:1481–91. https://doi.org/10.2147/IDR.S180908 . - DOI - PubMed - PMC
    1. Green ML et al. ‘CMV Viral Load and Mortality after Hematopoietic Cell Transplantation: A Cohort Study in the Era of Preemptive Therapy’, Lancet Haematol. 2016;3(3):e119–e127 https://doi.org/10.1016/S2352-3026(15)00289-6 .
    1. Lischka P et al. ‘In Vitro and In Vivo Activities of the Novel Anticytomegalovirus Compound AIC246’, Antimicrob. Agents Chemother. 2010;54(3):1290–1297. https://doi.org/10.1128/AAC.01596-09 .
    1. Goldner T, Hewlett G, Ettischer N, Ruebsamen-Schaeff H, Zimmermann H, Lischka P. ‘The Novel Anticytomegalovirus Compound AIC246 (Letermovir) Inhibits Human Cytomegalovirus Replication through a Specific Antiviral Mechanism That Involves the Viral Terminase ▿’, J. Virol. 2011;85(20):10884–10893. https://doi.org/10.1128/JVI.05265-11 .

LinkOut - more resources